GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dogwood Therapeutics Inc (NAS:DWTX) » Definitions » EBIT per Share

DWTX (Dogwood Therapeutics) EBIT per Share : $-6.02 (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Dogwood Therapeutics EBIT per Share?

Dogwood Therapeutics's EBIT per Share for the three months ended in Jun. 2024 was $-1.17. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $-6.02.

During the past 3 years, the average EBIT per Share Growth Rate was 47.70% per year. During the past 5 years, the average EBIT per Share Growth Rate was -2.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Dogwood Therapeutics's EBIT per Share or its related term are showing as below:

DWTX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -66.6   Med: -35.1   Max: 47.7
Current: 47.7

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Dogwood Therapeutics was 47.70% per year. The lowest was -66.60% per year. And the median was -35.10% per year.

DWTX's 3-Year EBIT Growth Rate is ranked better than
92.92% of 1257 companies
in the Biotechnology industry
Industry Median: 3.2 vs DWTX: 47.70

Dogwood Therapeutics's EBIT for the three months ended in Jun. 2024 was $-1.07 Mil.


Dogwood Therapeutics EBIT per Share Historical Data

The historical data trend for Dogwood Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dogwood Therapeutics EBIT per Share Chart

Dogwood Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Get a 7-Day Free Trial -11.29 -50.79 -46.97 -27.80 -7.25

Dogwood Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.01 -1.67 -1.48 -1.71 -1.17

Dogwood Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Dogwood Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-5.447/0.751
=-7.25

Dogwood Therapeutics's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

EBIT per Share(Q: Jun. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.07/0.916
=-1.17

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dogwood Therapeutics  (NAS:DWTX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Dogwood Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Dogwood Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Dogwood Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
44 Milton Avenue, Alpharetta, GA, USA, 30009
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ("FM") and Long-COVID ("LC"). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Executives
William Pridgen director 44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan director, officer: Chief Executive Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh officer: VP of Finance 44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel director 44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer director 44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald officer: Vice President of Operations 44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau officer: Chief Medical Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch director 44 MILTON AVENUE, ALPHARETTA GA 30009

Dogwood Therapeutics Headlines

From GuruFocus